Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.71 |
| ▸ | MAOB | P27338 | 4/20 | 0.71 |
| ▸ | IDO1 | P14902 | 2/20 | 0.66 |
| ▸ | AGXT | P21549 | 2/20 | 0.66 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | LPO | P22079 | 1/20 | 0.56 |
| ▸ | CMA1 | P23946 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42954 | 1.00 | TAAR1 (0.71) | TAAR1MAOBIDO1AGXTAOC3 | |
| Bromide SCHEMBL31513707 | 0.98 | TAAR1 (0.69) | TAAR1MAOBIDO1AGXTAOC3 | |
| Hydrochloric Acid SCHEMBL1275116 | 0.98 | MAOB (0.72) | TAAR1MAOBIDO1AGXTAOC3 | |
| SCHEMBL920587 | 0.92 | MAOB (0.63) | TAAR1MAOBIDO1AGXTAOC3 | |
| Hydrochloric Acid SCHEMBL18641342 | 0.91 | MAOB (0.64) | TAAR1MAOBIDO1AGXTAOC3 | |
| Hydrochloric Acid SCHEMBL18641293 | 0.91 | MAOB (0.64) | TAAR1MAOBIDO1AGXTAOC3 | |
| SCHEMBL921289 | 0.87 | MAOB (0.61) | TAAR1MAOBIDO1AGXTAOC3 | |
| Hydrochloric Acid SCHEMBL18641331 | 0.85 | MAOB (0.62) | TAAR1MAOBIDO1AGXTAOC3 | |
| Anisole SCHEMBL11636165 | 0.84 | LOXL2 (0.64) | TAAR1MAOBIDO1AGXTALDH1A1 | |
| SCHEMBL1680537 | 0.84 | MAOB (1.00) | TAAR1MAOBIDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116879-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4719385-A2 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS | University of Vermont and State Agricultural College (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4642764-A2 | AZAINDOLE ROCK INHIBITORS | Avicenna Biosciences, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12428413-B2 | Rho kinase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12415805-B2 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| CN-119816306-A | Treatment of Aplastic Anemia (AA) | 载度思生命科学有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20250092038-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2025-03-20 | — | — | US | disclosed |
| EP-4139286-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| WO-2024249380-A2 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024145569-A2 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| CN-117098767-A | METTL3 modulators | 埃克森特治疗公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230365546-A1 | 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | ORIGIANT PHARMACEUTICAL CO., LTD (CN) | 2023-11-16 | — | — | US | disclosed |
| EP-4212525-A1 | 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Origiant Pharmaceutical Co., Ltd (CN) | 2023-07-19 | — | — | EP | disclosed |
| WO-2023018472-A9 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| CN-116082435-A | Dipeptide and tripeptide immunoproteasome inhibitor and preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2023-05-09 | — | — | CN | disclosed |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-04 | — | — | US | disclosed |
| WO-2023018472-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20220388998-A1 | RHO KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2022-12-08 | — | — | US | disclosed |
| WO-2022187809-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428413-B2 | Rho kinase inhibitors and compositions and methods of use thereof | ROCK1, ROCK2, RHOA | TAAR1 4452/4885MAOB 775/4885IDO1 3978/4885 |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | TAAR1 3075/4885MAOB 4044/4885IDO1 1682/4885 |
| US-12415805-B2 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | TAAR1 3522/4885MAOB 2468/4885IDO1 1967/4885 |
| US-20230365546-A1 | 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | RIPK1, RIPK3, RIPK2 | TAAR1 1865/4885MAOB 1929/4885IDO1 10/4885 |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | TAAR1 3075/4885MAOB 4044/4885IDO1 1682/4885 |
| US-20220388998-A1 | RHO KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | ROCK1, ROCK2, RHOA | TAAR1 4452/4885MAOB 775/4885IDO1 3978/4885 |
| US-20260116879-A1 | AZAINDOLE ROCK INHIBITORS | PRKG2, PRKG1, ROCK2 | TAAR1 1784/4885MAOB 1428/4885IDO1 2524/4885 |
| US-20250092038-A1 | AZAINDOLE ROCK INHIBITORS | ROCK2, ROCK1, ARHGDIA | TAAR1 3522/4885MAOB 2468/4885IDO1 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.